Monia Garofolo
Overview
Explore the profile of Monia Garofolo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
171
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Garofolo M, Vitale M, Penno G, Solini A, Orsi E, Grancini V, et al.
Cardiovasc Diabetol
. 2024 Oct;
23(1):377.
PMID: 39449120
Background: A Chronic Kidney Disease (CKD) Epidemiology Collaboration (EPI) formula not including a Black race coefficient has been recently developed and is now recommended in the US. The new (2021)...
2.
Garofolo M, Penno G, Solini A, Orsi E, Vitale M, Resi V, et al.
Eur J Intern Med
. 2024 Jun;
128:53-62.
PMID: 38845288
Aims: To assess whether and to what extent excess risk of all-cause death is reduced in individuals with type 2 diabetes by achieving optimal control of traditional cardiovascular risk factors....
3.
Vitale M, Orsi E, Solini A, Garofolo M, Grancini V, Bonora E, et al.
Acta Diabetol
. 2024 May;
61(9):1107-1116.
PMID: 38714557
Aims: It is unclear whether type 2 diabetes diagnosed in young adulthood is associated with increased severity than that occurring later in life beyond longer lifetime exposure to hyperglycemia. This...
4.
Dardano A, Bianchi C, Garofolo M, Del Prato S
Atherosclerosis
. 2024 Apr;
394:117560.
PMID: 38688748
Despite the risk of atherosclerosis has progressively declined over the past few decades, subjects with type 2 diabetes mellitus (T2DM) continue to experience substantial excess of atherosclerotic cardiovascular disease (ASCVD)-related...
5.
Garofolo M, Lucchesi D, Giambalvo M, Aragona M, Bertolotto A, Campi F, et al.
Cardiovasc Diabetol
. 2024 Feb;
23(1):85.
PMID: 38419065
Background: Non-alcoholic fatty liver disease (NAFLD), identified by the Fatty Liver Index (FLI), is associated with increased mortality and cardiovascular (CV) outcomes. Whether this also applies to type 1 diabetes...
6.
Vitale M, Orsi E, Solini A, Garofolo M, Resi V, Bonora E, et al.
Cardiovasc Diabetol
. 2024 Jan;
23(1):34.
PMID: 38218843
Background: Foot ulcers and/or infections are common long-term complications of diabetes and are associated with increased mortality, especially from cardiovascular disease, though only a few studies have investigated the independent...
7.
Garofolo M, Penno G
Lancet Diabetes Endocrinol
. 2023 Oct;
11(12):880-881.
PMID: 37865100
No abstract available.
8.
Orsi E, Solini A, Bonora E, Vitale M, Garofolo M, Fondelli C, et al.
Diabetes Metab
. 2022 Dec;
49(2):101413.
PMID: 36460217
Aims: To assess whether the presence and grade of diabetic retinopathy (DR) predict all-cause mortality, independent of risk factors for cardiovascular disease (CVD) and other complications, including diabetes-related kidney disease...
9.
Garofolo M, Napoli V, Lucchesi D, Accogli S, Mazzeo M, Rossi P, et al.
Diabetes Metab Res Rev
. 2022 Oct;
39(1):e3585.
PMID: 36273390
Aims: Whether different diabetic kidney disease (DKD) phenotypes recognise differences in morphological and vascular properties of the kidney is still unexplored. We evaluated the potential role of kidney ultrasonography in...
10.
Falcetta P, Nicoli F, Citro F, Ciccarone A, Garofolo M, Del Prato S, et al.
Acta Diabetol
. 2022 Sep;
60(1):53-60.
PMID: 36166172
Aims: To evaluate the impact of adding a glucagon-like peptide-1 receptor agonist (GLP-1 RA) in people with type 2 diabetes (T2D) in basal-bolus (BB) insulin regimen, on insulin requirement, HbA1c,...